News
The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback